Ambu A/S Class B ( (AMBFF) ) has released its Q4 earnings. Here is a breakdown of the information Ambu A/S Class B presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ambu A/S is a medical technology company specializing in innovative solutions for endoscopy, anesthesia, and patient monitoring, with a focus on single-use devices. In its latest earnings report for Q4 2024/25, Ambu A/S reported a 10% organic revenue growth, driven by strong performances in its Endoscopy Solutions and Anesthesia & Patient Monitoring segments. The company’s EBIT margin before special items was 10%, slightly impacted by tariff costs and foreign exchange headwinds. For the full year, Ambu achieved a 13.1% organic growth and a 13% EBIT margin before special items. The company also launched its ‘ZOOM AHEAD’ strategy, aiming for global leadership in endoscopy by 2029/30. Looking forward, Ambu expects organic revenue growth of 10-13% for 2025/26, with an EBIT margin before special items projected at 12-14%, as it continues to mitigate tariff impacts and invest in growth initiatives.